Home > Selected Past Studies

SELECTED PAST STUDIES - Liquid Biopsies - Liquid Biopsies

Study

Disease

type & number of samples

Specific Requirements

associated data required

LB-1

Colorectal Cancer (KRAS)

Plasma and FFPE Blocks KRAS +

Prospective

More than 200 subjects

  • Newly Diagnosed patients with Colorectal Cancer stage IV
  • Blood samples collected before treatment
  • 20 to 40 40 ml plasma
  • Demographic, diagnostic and medical data
  • Stage
  • KRAS mutation status

LB-2

Non-Small Cell Lung Cancer (ALK)

Whole Blood and FFPE blocks Alk +

Prospective

More than 40 subjects

  • Whole blood collected in different types of tubes and shipped at room temperature
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

LB-3

Non-Small Cell Lung Cancer (EGFR)

Plasma

Prospective

More than 200 subjects

  • Stage III and IV NSCLC with mutated EGFR
  • Stage III and IV NSCLC non-smokers women and/or Asians
  • Plasma aliquoted
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come

LB-4

Non-Small Cell Lung Cancer (PD-L1)

Plasma

Prospective

More than 30 subjects

  • Positive for FFPE PD-L1 expression assessed by ICH
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

LB-5

Gastric Cancer

PBMC and FFPE Blocks

Retrospective

More than 50 subjects

  • Samples collected at diagnosis, before start of any treatment
  • PBMC isolated from 10 mL of blood
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Biomarker status: EGFR, KRAS,

LB-6

Skin, Lung and Colorectal cancers (BRAFK, EGFR, KRAS)

Urine

Prospective

4 groups:

  • Melanoma BRAF mutated
  • NSCLC EGFR mutated Stage IV
  • NSCLC KRAS mutated Stage IV
  • Colorectal KRAS mutated

 

  • Urine frozen at -80°C
  • Demographic, diagnostic and medical data
  • Stage
  • Treatment History
  • Date of tissue collection
  • Date of urine sampling